Catalyst Pharmaceuticals, Inc. (CPRX) Stock
Catalyst Pharmaceuticals, Inc.
Company profile
Catalyst Pharmaceuticals reported revenue of $588.99 million for fiscal year 2025, up 19.8% from fiscal year 2024, and net income of $214.33 million. That is a net profit margin of 36.4% for fiscal year 2025. Our analysis of its filings shows revenue growing from $398.20 million in fiscal year 2023 to $588.99 million in fiscal year 2025, 21.6% a year on average.
What stands out
- Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.
Figures from company filings; latest fiscal year ended December 31, 2025.
How much revenue does Catalyst Pharmaceuticals make?
Catalyst Pharmaceuticals reported $588.99 million in revenue for fiscal year 2025, up 19.8% from $491.73 million in fiscal year 2024.
What companies are similar to Catalyst Pharmaceuticals?
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include argenx SE (ARGX), Biogen Inc. (BIIB), Neurocrine Biosciences, Inc. (NBIX), Jazz Pharmaceuticals plc (JAZZ).
How has Catalyst Pharmaceuticals' revenue changed over the last 5 fiscal years?
Revenue by fiscal year: FY2021, $140.83 million; FY2022, $214.20 million; FY2023, $398.20 million; FY2024, $491.73 million; FY2025, $588.99 million.
Data as of .
How to cite: DataPorium, “Catalyst Pharmaceuticals, Inc. (CPRX)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/CPRX